See more : Security Matters Limited (SMX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of IGM Biosciences, Inc. (IGMS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IGM Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Starr Peak Mining Ltd. (STRPF) Income Statement Analysis – Financial Results
- Royal Wins Corporation (SKLL.CN) Income Statement Analysis – Financial Results
- Woojin I&S Co., Ltd. (010400.KS) Income Statement Analysis – Financial Results
- SeaCo Ltd. (SEAOF) Income Statement Analysis – Financial Results
- Novo Resources Corp. (NVO.TO) Income Statement Analysis – Financial Results
IGM Biosciences, Inc. (IGMS)
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.13M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| Gross Profit | -6.15M | -9.53M | -7.72M | -3.58M | -2.33M | -278.00K | -161.00K |
| Gross Profit Ratio | -288.59% | -891.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 215.52M | 179.29M | 127.03M | 65.03M | 35.26M | 18.96M | 8.64M |
| General & Administrative | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Other Expenses | 0.00 | -181.00K | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Operating Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Cost & Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Interest Income | 17.74M | 7.04M | 159.00K | 1.93M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| EBITDA | -253.36M | -221.88M | -157.44M | -77.78M | -40.80M | -22.51M | -10.99M |
| EBITDA Ratio | -11,894.74% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -263.46M | -227.96M | -165.32M | -83.28M | -44.50M | -22.79M | -11.15M |
| Operating Income Ratio | -12,369.06% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.72M | 6.85M | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Income Before Tax | -245.74M | -221.10M | -165.16M | -81.36M | -43.13M | -22.71M | -11.05M |
| Income Before Tax Ratio | -11,537.00% | -20,683.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 678.00K | -6.85M | -4.48M | -1.03M | -597.00K | 80.00K | 0.00 |
| Net Income | -246.42M | -214.25M | -160.68M | -80.33M | -42.54M | -22.71M | -11.05M |
| Net Income Ratio | -11,568.83% | -20,041.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| EPS Diluted | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| Weighted Avg Shares Out | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
| Weighted Avg Shares Out (Dil) | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
Medivir's patent application for fostrox approved in China
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima
IGM Biosciences to Present at the Jefferies Healthcare Conference
Medivir to present at the Redeye Growth Day
IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis
Change in the number of shares and votes in Medivir AB (publ)
IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
Medivir to present at the ABGSC Life Science Summit
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023
Source: https://incomestatements.info
Category: Stock Reports